Japan Pharma Lobbies Likely to Retain Chiefs as Off-Year Re-Pricing Debate Looms

FPMAJ Chairman Isao Teshirogi (left), JPMA President Joji Nakayama Two key Japanese pharma trade groups are expected to keep intact their chieftains for now to deal with upcoming discussions on so-called “off-year” re-pricing as the government plans to define the...read more